Gabriel Tinoco Suarez, MD
Medical Oncology · Columbus, OHNPI 1053564542
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Deciphera Pharmaceuticals Inc. at 57.9% of the total. 2025 is the largest year on record at $11,936, more than ten times the $22 reported in 2020.
Across 36 payments — averaging $783.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$16K
- EMD Serono Research & Development Institute, Inc.$5K
- Daiichi Sankyo Inc.$4K
- Servier Pharmaceuticals LLC$3K
- Gilead$91
- Servier Bioinnovation$65
- plus $22 from 1 others
Across 240 payments — averaging $6862.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Deciphera Pharmaceuticals Inc.$1.2M
- Servier Bioinnovation$280K
- Boehringer Ingelheim$59K
- Novartis$39K
- Trillium Therapeutics USA, LLC$30K
- Springworks Therapeutics, Inc.$29K
- plus $30K from 3 others
What the payments were for
- Consulting fees$11,55341%
- Speaking & faculty fees$13,56048%
- Travel & lodging$2,0277%
- Food & beverage$8693%
- Gifts$2121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 26 | $16,337 |
| EMD Serono Research & Development Institute, Inc. | 1 | $4,750 |
| Daiichi Sankyo Inc. | 5 | $4,155 |
| Servier Pharmaceuticals LLC | 1 | $2,800 |
| Gilead | 1 | $91 |
| Servier Bioinnovation | 1 | $65 |
| Amgen | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIMSELTINIB$7,342
- QINLOCK$5,608
- Turalio$4,003
- ROMVIMZA$2,856
- TIBSOVO$2,800
How this compares
$28,221 in reported general payments places this provider in the 85th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OgsiveoNirogacestat Hydrobromide | 24 | $660,303 |
| VotrientPazopanib Hcl | 14 | $94,287 |
| Imatinib Mesylate | 30 | $49,076 |
| Prochlorperazine Maleate | 13 | $165 |
| Gabapentin | 13 | $118 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Columbus
- David CarboneColumbus$438K
- Christian RolfoColumbus$227K
- Timothy MooreColumbus$213K
- Maryam LustbergColumbus$176K
- Timothy BurnsColumbus$64K
- Kai HeColumbus$49K
- Gregory OttersonColumbus$49K
- Sagar SardesaiColumbus$45K
- Asrar AlahmadiColumbus$36K
- John HaysColumbus$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.